GU Cancers 2023 | Using SBRT to delay systemic therapy for patients with oligometastatic RCC

Shankar Siva, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses several recent trials whose results supported the use of stereotactic body radiotherapy (SBRT) to delay systemic therapy for patients with low-volume recurrent kidney cancer. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.